UPCC 07623 Effect of Immune Checkpoint Inhibitors on Coronary Microvasculature

Investigation of Immune Checkpoint Inhibitors on Heart Health in Cancer Patients

UPCC 07623 Effect of Immune Checkpoint Inhibitors on Coronary Microvasculature
Enrolling By Invitation
18 years or above
All
Phase N/A
25 participants needed
1 Location

Brief description of study

This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • ≥18 years of age
  • Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
  • Able to provide written informed consent

Exclusion Criteria:

  • Pregnant or breast-feeding:
  • Prior treatment with ICI therapy.
  • Vulnerable patients, including pregnant women and prisoners
  • Absolute Contraindication to rest/vasodilator stress PET/CT

The purpose of this study is to investigate the effects of immune checkpoint inhibitors (ICI) on the heart and circulatory system in patients with breast cancer or non-small cell lung cancer. This study focuses on understanding how these medications, which are used in cancer treatment, might impact heart health. An observational study is a type of research study where data is collected by observing participants receiving routine care, without changing their treatment.

Participants in this study will undergo various procedures to assess heart health, including echocardiograms, blood draws, and PET stress tests. These procedures will help researchers gather data on how the ICI therapy affects the coronary microvasculature, which is the network of small blood vessels in the heart.

  • Who can participate: Adults 18 years or older with a diagnosis of breast cancer or non-small cell lung cancer, who are planning to receive specific cancer treatments, are eligible. Participants must be able to provide informed consent. Exclusion criteria include not being pregnant or breastfeeding and having no prior ICI therapy.
  • Study details: Participants will be involved in heart health assessments using echocardiograms, blood draws, and PET stress tests to observe the effects of immune checkpoint inhibitors on the heart.
Updated on 25 Aug 2026. Study ID: 23-1777
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator